$AGMB News
Last published 1w ago
- 1w agoAGMBAgomab to Participate in Upcoming Investor ConferencesGlobeNewswireAntwerp, Belgium, November 4, 2026 – Agomab Therapeutics NV (NASDAQ:AGMB) ("Agomab"), a clinical-stage biopharmaceutical company focused on fibro-inflammation, today announced that members of the management team
- 4w agoAGMBAgomab Announces First Patient Dosed in Global NOV-ERA Phase 2b Study of Ontunisertib in Fibrostenosing Crohn's DiseaseGlobeNewswire-- NOV-ERA is designed to assess the efficacy and safety of ontunisertib in approximately 320 patients with symptomatic Fibrostenosing Crohn's disease (FSCD) -- -- Global, randomized, placebo-controlled,
- 1mo agoAGMBAgomab to Present STENOVA Open-Label Extension Data of Ontunisertib at UEG Week 2026 and Host Scientific Symposium on Fibro-InflammationGlobeNewswire-- Open-Label Extension (OLE) Data of STENOVA Phase 2a study with ontunisertib in Fibrostenosing Crohn’s disease (FSCD) selected for oral presentation at UEG Week 2026 -- -- Results support initiation of global NOV-ERA
- 1mo agoAGMBAgomab Announces Positive Phase 1 Results for AGMB-447 in Patients with Idiopathic Pulmonary Fibrosis and Design of Phase 2 INSPIRIA StudyGlobeNewswire-- Topline Phase 1 data shows generally favorable safety and tolerability profile of AGMB-447 -- -- Pharmacokinetic profile confirms efficient lung restriction with low systemic exposure and high exposure of AGMB-447
- 2mo agoAGMBAgomab Announces Appointments of Marino Garcia and Dr. Naimish Patel to Board of DirectorsGlobeNewswireAntwerp, Belgium, September 11, 2026 – Agomab Therapeutics NV (NASDAQ:AGMB) ("Agomab" or the "Company"), a clinical-stage biopharmaceutical company focused on fibro-inflammatory diseases, today announced
- 2mo agoAGMBAgomab to Participate in Upcoming Investor ConferencesGlobeNewswireAntwerp, Belgium, September 3, 2026 – Agomab Therapeutics NV (NASDAQ:AGMB) ("Agomab"), a clinical-stage biopharmaceutical company focused on fibro-inflammation, today announced that members of the management
- 3mo agoAGMBDNTHCRSPAgomab Announces Proposed Appointments of Marino Garcia and Dr. Naimish Patel to Board of DirectorsGlobeNewswireAntwerp, Belgium, August 10, 2026 – Agomab Therapeutics NV (NASDAQ:AGMB) ("Agomab" or the "Company"), a clinical-stage biopharmaceutical company focused on fibro-inflammatory diseases, today announced
- 3mo agoAGMBAgomab Reports Half Year 2026 Financial Results and Confirms 2026 OutlookGlobeNewswire-- Regulatory alignment with U.S. Food and Drug Administration (FDA) on key elements of NOV-ERA Phase 2b study design with Ontunisertib in Fibrostenosing Crohn’s Disease (FSCD), including Novel Primary Endpoint of
- 4mo agoAGMBAgomab Announces Design of NOV-ERA Phase 2b Study with Ontunisertib in Fibrostenosing Crohn’s DiseaseGlobeNewswire-- Regulatory alignment with U.S. Food and Drug Administration (FDA) on key elements of NOV-ERA Phase 2b study design, including novel primary endpoint of endoscopic passability -- -- Study initiation on track, with
- 5mo agoAGMBAgomab Announces Results of Annual General MeetingGlobeNewswireAntwerp, Belgium, May 27, 2026 – Agomab Therapeutics NV (NASDAQ:AGMB) ("Agomab"), a clinical-stage biopharmaceutical company focused on fibro-inflammation, today announced the results of its Annual General Meeting (AGM)
- 6mo agoAGMBAgomab to Participate in Upcoming ConferencesGlobeNewswireAntwerp, Belgium, May 14, 2026 – Agomab Therapeutics NV (NASDAQ:AGMB) ("Agomab"), a clinical-stage biopharmaceutical company focused on fibro-inflammation, today announced that members of the management team will
- 6mo agoAGMBAgomab Reports Full Year 2025 Financial Results and Confirms 2026 OutlookGlobeNewswire-- Cash and Cash Investments at December 31, 2025 of €116.5 Million and Gross Proceeds of $208 Million from Initial Public Offering (IPO) Expected to Extend Cash Runway into First Half of 2029 -- -- Positive
- 7mo agoAGMBAgomab Receives U.S. Patent for AGMB-447, its Inhaled Lung-restricted Small Molecule Inhibitor of ALK5 in Development for the Treatment of Idiopathic Pulmonary FibrosisGlobeNewswireAntwerp, Belgium, March 26, 2026 – Agomab Therapeutics NV (NASDAQ:AGMB) ("'Agomab'"), a clinical-stage biopharmaceutical company focused on fibrosis, today announced that the United States Patent and Trademark Office
- 9mo agoAGMBAgomab Announces Closing of Initial Public OfferingGlobeNewswireANTWERP, Belgium, February 9, 2026 (GLOBE NEWSWIRE) – Agomab Therapeutics NV (NASDAQ:AGMB) ("Agomab"), a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and
- 9mo agoAGMBAgomab Announces Pricing of Initial Public OfferingGlobeNewswireANTWERP, Belgium, February 5, 2026 (GLOBE NEWSWIRE) – Agomab Therapeutics NV (NASDAQ:AGMB) ("Agomab"), a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and